Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 16.82 USD -0.94%
Market Cap: 819.8m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Uniqure NV
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Cash from Operating Activities
-$179.4m
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
-19%
Pharming Group NV
AEX:PHARM
Cash from Operating Activities
$451k
CAGR 3-Years
-79%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Cash from Operating Activities
-€32.4m
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Cash from Operating Activities
-$259.5m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Cash from Operating Activities
-$155.5m
CAGR 3-Years
-44%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Cash from Operating Activities
-$39m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
819.8m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Uniqure NV's Cash from Operating Activities?
Cash from Operating Activities
-179.4m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Cash from Operating Activities amounts to -179.4m USD.

What is Uniqure NV's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-19%

Over the last year, the Cash from Operating Activities growth was -19%.

Back to Top